Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Positive margins more than doubled mortality risk and quadrupled local recurrence risk in a meta-analysis of 2,438 post-radiation sarcoma patients.
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.
Leave-one-cancer-type-out genomic scores remained associated with progression in five of eight cancers, with the largest performance gain in cervical cancer.
AI-assisted planning cut average planning time from about two hours to 30 minutes, but three of 12 plans required manual hotspot correction.
A phantom-derived model predicted SCART central target radius with R² values of 0.991–0.999, but clinical validation remains absent.
In 20 vulvar cancer patients, SGRT reduced pitch error from 1.21° to 0.07° and longitudinal error from 4.9 to 0.4 mm.
A scanned helium beamline achieved submillimetre range accuracy and generally ≤3% dose agreement, supporting further translation toward clinical helium therapy.
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
The programme prepared 256 children for radiotherapy and was associated with avoidance of daily general anaesthesia in five selected cases.
Grade ≥2 urinary toxicity fell from 22% at two weeks to 3% at six months, with almost no clinically significant bowel toxicity.
None of four selected blood-biomarker domains currently supports treatment personalization, and sampling schedules frequently failed to match expected biological kinetics.